[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637564":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":60,"collaborators":26,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":26,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":26,"overallStatus":81,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Test Group","EXPERIMENTAL","ZG006 Q2W",[13],"Biological: ZG006",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","ACTIVE_COMPARATOR","Investigator-selected chemotherapy (such as FOLFIRI regimen)",[19],"Drug: 5-fluorouracil, Calcium folinate and Irinotecan",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","ZG006","ZG006 will be administered as an intravenous (IV) infusion.",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","5-fluorouracil, Calcium folinate and Irinotecan","Irinotecan 180 mg\u002Fm\\^2, Calcium folinate 400 mg\u002Fm\\^2, 5-Fluorouracil: 400 mg\u002Fm\\^2 by intravenous infusion on Day 1; 5-Fluorouracil: 2400 mg\u002Fm\\^2 by continuous intravenous infusion over 46 to 48 hours， once two weeks.",[15],[33],"FOLFIRI",[35],{"name":36,"affiliation":5,"role":37},"Jason Wu","STUDY_CHAIR",[39],{"name":40,"role":41,"phone":42,"phoneExt":26,"email":43},"Shangdi Ning","CONTACT","+86-0512-57309965","ningsd@zelgen.com",[45],{"facility":46,"status":26,"city":47,"state":48,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","China","CN",{"type":52,"coordinates":53},"Point",[54,55],113.64861,34.75778,{"lat":55,"lon":54},[58],{"name":59,"role":41,"phone":26,"phoneExt":26,"email":26},"Lijie Song",{"type":61,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100637564","phase-3-a-study-of-zg006-for-injection-versus-investigator-selected-chemotherapy-in-participants-with-advanced-neuroendocrine-carcinoma-100637564",false,"NCT07595913","A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma","A Phase III, Multicenter, Randomized, Open-Label, Controlled Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma","Inclusion Criteria:\n\n* Has provided written informed consent voluntarily after being fully informed about the study.\n* Male or female, aged 18 to 75 years (inclusive) at the time of informed consent signing.\n* Histologically or cytologically confirmed advanced neuroendocrine carcinoma (NEC); small cell lung cancer (SCLC) and combined SCLC are excluded. Additionally, the Participants with DLL3-positive NEC who have received prior systemic therapy (second-line and above)..\n\nExclusion Criteria:\n\n* Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in this study.","ALL","18 Years","75 Years",{"count":73,"type":74},240,"ESTIMATED","INTERVENTIONAL",[77],"PHASE3","This Phase III, multicenter, randomized, open-label, controlled study is designed to assess the efficacy and safety of ZG006 versus investigator-selected chemotherapy in participants with DLL3-positive advanced neuroendocrine carcinoma who have received prior systemic therapy.",[80],"Neuroendocrine Carcinoma","NOT_YET_RECRUITING","2026-05-13",{"date":84,"type":85},"2026-05-19","ACTUAL",{"date":87,"type":74},"2026-07",{"date":89,"type":74},"2028-12",{"name":5,"class":6},1]